Carfilzomib shined in pharmaceutical headlines recently with encouraging study data being shared in June 2015. Known as the brand name anticancer therapy Kyprolis, which is marketed by Onyx, the Carfilzomib injection proved to be superior to a Bortezomib-Dexamethasone combination treatment in patients with refractory multiple myeloma. Carfilzomib is an effectual single-agent therapy and proteasome inhibitor[…]
Carfilzomib Shines in Studies of Patients with Relapsed Myeloma
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API Tags: Bortezomibmultiple myeloma Sep 16, 2015
Pomalidomide Now Approved to Treat Multiple Myeloma
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, Immunological Agent Tags: BortezomibLenalidomidemelanomamultiple myeloma Feb 20, 2013
February 8, 2013 – Pomalidomide Now Approved by the FDA to Treat Multiple Myeloma under the FDA’s accelerated approval program. Pomalidomide therapy was also granted orphan product designation as it is intended to treat a rare disease. Marketed as Pomalyst by Celgene, Pomalidomide, CAS 19171-19-8, is a last chance treatment for patients with Multiple Myeloma[…]
Will Bortezomib Meet the WHO Need for Future Cancer Treatments?
Bulk Active Ingredient, Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, Patent Expiration 2017 Tags: Bortezomibmantle cell lymphomamultiple myelomaWHO Jan 31, 2013
The World Health Organization has predicted over 20 million new cancer cases in 2015 worldwide. This seemingly unbelievable number is not only astonishing; it is also a dire warning from the WHO. With the future onslaught of patients needing cancer care and treatments, the WHO has been urging researchers to continue to develop new products[…]
Prepare for the Future Exaction of Oncology Products
Drug Research & Development API, Immunological Agent, Immunosuppressant Tags: 159351-69-6191732-72-6acute lymphoblastic leukemiaBortezomibEverolimusLenalidomideleukemiamultiple myeloma Jul 05, 2012
The Oncology segment of the pharmaceutical industry is not only a fast growing one, but it is also an area where shortages are anticipated. A decrease in availability of sterile injectable oncology drugs have been reported since 2007. Furthermore, many of the sterile injectable oncology drugs that experienced shortages in 2010 and 2011 had a[…]
